Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Single Arm, Multicenter Study of Avelumab With Hypofractionated Radiation in Adult Subjects With Transformed IDH Mutant Glioblastoma

NCT02968940 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT02968940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02968940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Single Arm, Multicenter Study of Avelumab With Hypofractionated Radiation in Adult Subjects With Transformed IDH Mutant Glioblastoma
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Completed
Start date
March 17, 2017
Completion date
August 29, 2019
Enrollment
6 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma